Ptc Therapeutics (PTCT) Asset Writedowns and Impairment (2023 - 2025)

Ptc Therapeutics' Asset Writedowns and Impairment history runs 3 years deep, the most recent figure standing at $518000.0 for Q4 2025.

• On a quarterly basis, Asset Writedowns and Impairment fell 99.67% year-over-year to $518000.0 in Q4 2025; TTM through Dec 2025 was $159.1 million, a 0.3% change from a year earlier, with the FY2025 full-year figure at $1.0 million, down 99.36% from the prior year.
• Asset Writedowns and Impairment improved to $518000.0 in Q4 2025 per PTCT's latest filing, from $400000.0 in the prior quarter.
• Across five years, Asset Writedowns and Impairment topped out at $217.8 million in Q2 2023 and bottomed at $100000.0 in Q2 2025.
• The 3-year median for Asset Writedowns and Impairment is $518000.0 (2025), against an average of $54.1 million.
• Across the five-year window, Asset Writedowns and Impairment sank 99.91% in 2024 and sank 50.0% in 2025, its largest moves.
• Year by year, Asset Writedowns and Impairment stood at $217.8 million in 2023, then retreated by 27.43% to $158.1 million in 2024, then slumped by 99.67% to $518000.0 in 2025.
• Per Business Quant, the three latest PTCT Asset Writedowns and Impairment figures stand at $518000.0 (Q4 2025), $400000.0 (Q3 2025), and $100000.0 (Q2 2025).